articleTop 1% cited
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active‐surveillance report
Arthritis & Rheumatism · 2003 · Vol. 48(8) · pp. 2122–2127
Juan J. Gómez‐Reino✉(Complejo Hospitalario Universitario de Santiago)Loreto Carmona(Hospital Clínico San Carlos)Vicente Rodríguez Valverde(Universidad de Cantabria)Emilio Martín Mola(Hospital Universitario La Paz)Maria Dolores Montero(Agencia Española de Medicamentos y Productos Sanitarios)
Abstract
Therapy with infliximab is associated with an increased risk of active TB. Proper measures are needed to prevent and manage this adverse event.
Tuberculosis Research and EpidemiologyInfectious Diseases and TuberculosisRheumatoid Arthritis Research and TherapiesRheumatoid arthritisMedicineTuberculosisTumor necrosis factor alphaTumor necrosis factor αImmunologyRisk factorInternal medicineAntirheumatic AgentsOncology
MeSH terms
EtanerceptInfliximabAdultAgedAged, 80 and overAntibodies, MonoclonalArthritis, RheumatoidFemaleHumansImmunoglobulin GImmunosuppression TherapyMaleMiddle AgedRegistriesRetrospective Studies
Funding
- Sociedad Española de Reumatología
Citations
1,011
FWCI
31.79
field-weighted impact
References
11
Percentile
100%
vs. same field & year
Citations per year
Cited by
British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
British Journal of Dermatology · 2009 · 433 citations
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
Lara D. Veeken · 2012 · 531 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.